Tramadol allows reduction of naproxen dose among patients with naproxen- responsive osteoarthritis pain: A randomized, double-blind, placebo- controlled study

Arthritis and Rheumatism

Volumn 42, Issue 7, 1999, Pages 1370-1377

  Schnitzer, Thomas J ^a   Kamin, Marc ^b   Olson, William H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; PLACEBO; TRAMADOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOLOGY; SCORING SYSTEM; SOMNOLENCE; STOMACH ULCER; VERTIGO;

AGED; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; PAIN; PLACEBOS; SINGLE-BLIND METHOD; THERAPEUTIC EQUIVALENCY; TRAMADOL;

EID: 0033512395     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199907)42:7<1370::AID-ANR10>3.0.CO;2-T     Document Type: Article

References (22)

1. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
2. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
3. Griffin MR, Ray WA, Schaffner W. Nonsteroidal antiinflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
4. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1993;343:769-72.
5. Langman MJS, Weil J, Wainright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343: 1075-8.
6. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly person at higher risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
7. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260:275-85.
8. Roth SA. Efficacy and safety of tramadol HCl in breakthrough osteoarthritis pain. J Rheumatol 1998;25:1358-63.
9. Dalgin P, and the TPS-OA Study Group. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis [abstract]. Arthritis Rheum 1997;40 Suppl 9:S86.
10. Cicero TJ, Senay E, Munoz A. Proactive surveillance program to assess Ultram (tramadol) abuse [abstract]. Pharmacoepidemiol Drug Safety 1998;7:S215.
11. Henry D, Lim LL, Garcia-Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
12. Perez Gutthann S, Garcia-Rodriguez LA, Raiford DS, Deque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-9.
13. Katz WA. The role of tramadol in the management of musculoskeletal pain. Today's Therapeutic Trends 1995;13:177-86.
14. Barkin RL. Alternative dosing for tramadol aids effectiveness [letter]. Formulary 1995;30:542-3.
15. Ruoff GE. An evaluation of varying titration rates of tramadol HCl in patients with chronic joint pain. Pharmacotherapy 1999;19:88-93.
16. Day RO, Brooks P. Variations in response to non-steroidal anti-inflammatory drugs. Br J Pharmacol 1987;23:655-8.
17. Høyerall HM, Fagertun H, Ingemann-Hansen T, Ersmark H, Ronn O. Characterization of responders and nonresponders to tiaprofenic acid and naproxen in the treatment of patients with osteoarthritis. J Rheumatol 1993;20:1747-52.
18. Walker JS, Arroyo JF, Nguyen T, Day RO. Analgesic efficacy of nonsteroidal anti-inflammatory drugs in experimental pain in humans. Br J Clin Pharmacol 1993;36:417-25.
19. Walker JS, Nguyen TV, Day RO. Response to nonsteroidal anti-inflammatory drugs in urate-crystal induced inflammation; a simultaneous study of intersubject and intrasubject variability. Br J Clin Pharmacol 1994;38:341-7.
20. Baber N, Halliday LDC, van den Heuvel WJA, Walker RW, Sibeon R, Keenan JP, et al. Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders. Ann Rheum Dis 1979;38:128-37.
21. Walker JS, Sheather-Reid RB, Carmondy JJ, Vial JH, Day RO. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of "responders" and "non-responders." Arthritis Rheum 1997;40:1944-54.
22. Rauck RL, Ruoff GE, McMillen JI. Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Ther Res 1994;55:1417-31.